Thanks to an electronic device, those with severe injuries—even paraplegics—could be walking again soon. Initially tested at MossRehab in Philadelphia, this device has now been approved by the FDA and can be used outside of the hospital environment. Described by MossRehab as a “motorized exoskeleton suit, ” the ReWalk uses motion sensors and measures a patient’s upper body movements and shifts in gravity.
Paraplegics Could Walk Again: FDA Approves ReWalk
1 min read Premium comments
Secondary
" data-large-file="https://i0.wp.com/ryortho.com/wp-content/uploads/2014/07/Paraplegics_ReWalk_WEB.jpg?fit=730%2C482&ssl=1" src="https://i0.wp.com/ryortho.com/wp-content/uploads/2014/07/Paraplegics_ReWalk_WEB.jpg?resize=730%2C482&ssl=1" alt="ReWalk / Source: Einstein Healthcare Network" width="730" height="482">ReWalk / Source: Einstein Healthcare Network
Alberto Esquenazi, M.D., chief medical officer at MossRehab, said in the July 2, 2014 news release, “This is an incredible step forward in allowing patients who normally would be unable to walk, who are dependent on wheelchairs, to now be able to use a device that will permit them walking mobility around their house and the community.
Asked about the product development, Dr. Esquenazi told OTW, “We helped improve the device design and the algorithm that makes the system walk. We also demonstrated the functional outcome of achieving seat-to-stand and ambulation for patients who otherwise are completely paralyzed.”
As for what might be especially challenging for patients regarding training, he commented to OTW, “Learning where their balance is during standing and walking in view of lack of sensation in their legs as a result of the spinal cord injury.”
MossRehab is part of Einstein Healthcare Network.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.